Please use this identifier to cite or link to this item: https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3860
Journal Title: Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post-Hoc Analysis of the EXTEND-IA TNK Trials
Authors: Yogendrakumar, Vignan
Churilov, Leonid
Mitchell, Peter J.
Kleinig, Timothy J.
Yassi, Nawaf
Thijs, Vincent
Wu, Teddy
Shah, Darshan
Bailey, Peter
Dewey, Helen M.
Choi, Philip M.
Ma, Alice
Wijeratne, Tissa
Garcia-Esperon, Carlos
Cloud, Geoffrey
Chandra, Ronil V.
Cordato, Dennis J.
Yan, Bernard
Sharma, Gagan
Desmond, Patricia M.
Parsons, Mark W.
Donnan, Geoffrey A.
Davis, Stephen M.
Campbell, Bruce C. V.
Keywords: Tenecteplase
Alteplase
Tandem Lesion Stroke
EXTEND-IA TNK Trials
Stroke
Issue Date: May-2023
Date Accessioned: 2023-04-24T02:44:24Z
Date Available: 2023-04-24T02:44:24Z
Accession Number: 36878701
Url: https://www.ncbi.nlm.nih.gov/pubmed/36878701
Description Affiliation: Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia vyogendrakum@student.unimelb.edu.au.
Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, Parkville, Australia.
Melbourne Medical School, University of Melbourne, Heidelberg, Australia.
Department of Radiology, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia.
Department of Neurology, Royal Adelaide Hospital, Adelaide, Australia.
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia.
Department of Neurology, Christchurch Hospital, Christchurch, New Zealand.
Department of Neurology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Department of Neurology, Gold Coast University Hospital, Queensland, Australia.
Eastern Health and Eastern Health Clinical School, Department of Neurosciences, Monash University, Clayton, Victoria, Australia.
Royal North Shore Hospital, New South Wales, Australia.
Melbourne Medical School, Department of Medicine and Neurology, The University of Melbourne and Western Health, Sunshine Hospital, St Albans Victoria, Australia.
Department of Neurology, John Hunter Hospital, Newcastle, New South Wales, Australia.
Department of Neurology, Alfred Hospital, Melbourne, Australia.
Department of Neuroscience, Central Clinical School, Monash University, Melbourne.
NeuroInterventional Radiology Unit, Monash Health, Monash University, Australia.
Department of Neurology, Liverpool Hospital, University of New South Wales, Sydney, Australia.
Database: Publisher
DOI: 10.1212/WNL.0000000000207138
Date: Mar 6
NLM
2023
Abstract: BACKGROUND AND OBJECTIVE: The safety and efficacy of tenecteplase in patients with tandem lesion stroke is unknown. We performed a comparative analysis of tenecteplase versus alteplase in patients with tandem lesions. METHODS: We first compared the treatment effect of tenecteplase and alteplase in patients with tandem lesions using individual patient data from the EXTEND-IA TNK trials. We evaluated intracranial reperfusion at initial angiographic assessment and 90-day mRS with ordinal logistic and Firth regression models. Because two key outcomes, mortality and symptomatic intracranial hemorrhage, were few in number among those who received alteplase in the EXTEND-IA TNK trials, we generated pooled estimates for these outcomes by supplementing trial data with estimates of incidence obtained through a meta-analysis of studies identified in a systematic review. We then calculated unadjusted risk differences to compare the pooled estimates for those receiving alteplase with the incidence observed in the trial among those receiving tenecteplase. RESULTS: Seventy-one of 483 patients (15%) in the EXTEND-IA TNK trials possessed a tandem lesion. In tandem lesion patients, intracranial reperfusion was observed in 11/56 (20%) of tenecteplase treated patients vs. 1/15 (7%) alteplase treated patients (aOR: 2.19; 95% CI:0.28-17.29). No significant difference in 90-day mRS was observed (adjusted common OR: 1.48; 95% CI: 0.44-5.00). A pooled study-level proportion of alteplase associated mortality and symptomatic intracranial hemorrhage was 0.14 (95% CI: 0.08-0.21) and 0.09 (95% CI: 0.04-0.16), respectively. Compared to a mortality rate of 0.09 (95% CI: 0.03-0.20) and a symptomatic intracranial hemorrhage rate of 0.07 (95% CI: 0.02-0.17) in tenecteplase treated patients, no significant difference was observed. CONCLUSIONS: Functional outcomes, mortality, and symptomatic intracranial hemorrhage did not significantly differ between tenecteplase and alteplase treated tandem lesion patients. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that tenecteplase is associated with similar rates of intracranial reperfusion, functional outcome, mortality, and symptomatic intracranial hemorrhage compared with alteplase, in patients with acute stroke due to tandem lesions. However, the confidence intervals do not rule out clinically important differences.
URI: https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3860
Journal Title: Neurology
Type: Journal Article
Appears in Collections:SWH Data Contributions

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing